Literature DB >> 31616949

Evaluation of rapid diagnostic tests and conventional enzyme-linked immunosorbent assays to determine prior dengue infection.

Matthew Bonaparte1, Lingyi Zheng2, Sanjay Garg1, Bruno Guy3, Yaniv Lustig4, Eli Schwartz5, Carlos A DiazGranados6, Stephen Savarino7, Yasemin Ataman-Önal8.   

Abstract

BACKGROUND: In September 2018, the World Health Organization recommended that prevaccination screening be used with the tetravalent dengue vaccine (CYD-TDV), to ensure that only individuals with evidence of prior dengue infection (PDI) are vaccinated. Dengue rapid diagnostic tests (RDTs) would offer a potential solution for prevaccination screening at the point-of-care, but data on performance of available RDTs for identifying PDI are limited. We determined the suitability of four dengue RDTs and two conventional enzyme-linked immunosorbent assays (ELISAs) to identify PDI and evaluated cross-reactivity with co-circulating flaviviruses.
Methods: Specificity was assessed using 534 dengue-negative [determined by 50% plaque reduction neutralization test (PRNT50)] serum samples from USA (n = 229) and dengue-endemic regions (n = 305). Sensitivity was assessed using 270 samples from recent (n = 90) or remote (n = 90) virologically confirmed prior dengue cases, and dengue PRNT50-positive samples (n = 90). Cross-reactivity was assessed in dengue-seronegative samples that were seropositive for yellow fever (n = 57), Japanese encephalitis (n = 37), West Nile (n = 59) or Zika (n = 41).
Results: Dengue IgG RDTs and the Panbio ELISA exhibited favourable specificities (99-100%), higher than the Focus ELISA (95%). The RDTs had variable sensitivities (40-70%) that were lower than those of the ELISAs (≥90%). Cross-reactivity to other flaviviruses was low with RDTs (≤7%), but more significant with ELISAs (up to 51% for West Nile and 34% for Zika). No cross-reactivity to any of the four closely related flaviviruses was observed with the CTK Biotech RDT. For each SeroTest, sensitivity appeared similar in samples from individuals with recent (<13 months) vs remote (3-4 years) virologically confirmed PDI. Conclusions: In general, dengue IgG RDTs were found to be more specific and less cross-reactive than the ELISAs, but the latter were more sensitive for identifying PDI cases. Currently available RDTs could be temporizing tools for rapid and safe prevaccination screening until improved RDTs with increased sensitivity become available. © International Society of Travel Medicine 2019. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  CYD-TDV; Dengue vaccine; Dengvaxia; cross-reactivity; flavivirus; prevaccination screening; serostatus testing

Year:  2019        PMID: 31616949     DOI: 10.1093/jtm/taz078

Source DB:  PubMed          Journal:  J Travel Med        ISSN: 1195-1982            Impact factor:   8.490


  11 in total

Review 1.  Historical discourse on the development of the live attenuated tetravalent dengue vaccine candidate TV003/TV005.

Authors:  Anna P Durbin
Journal:  Curr Opin Virol       Date:  2020-10-23       Impact factor: 7.090

2.  Performance Evaluation of a Dengue IgG Rapid Diagnostic Test Designed to Determine Dengue Serostatus as Part of Prevaccination Screening.

Authors:  Vasco Liberal; Remi Forrat; Cong Zhang; Charles Pan; Matthew Bonaparte; Wushan Yin; Lingyi Zheng; Valeria Viscardi; Yukun Wu; Yasemin Ataman-Önal; Stephen Savarino; Catherine Chen
Journal:  Microbiol Spectr       Date:  2022-05-23

3.  Integrated serological surveillance of acute febrile illness in the context of a lymphatic filariasis survey in Timor-Leste: a pilot study using dried blood spots.

Authors:  Paul Arkell; Julia Angelina; Alberina do Carmo Vieira; Johanna Wapling; Ian Marr; Merita Monteiro; Alexander Matthews; Salvador Amaral; Virginia da Conceicao; Sung Hye Kim; Daniel Bailey; Jennifer Yan; Nicholas S S Fancourt's; Susana Vaz Nery; Joshua R Francis
Journal:  Trans R Soc Trop Med Hyg       Date:  2022-06-01       Impact factor: 2.455

Review 4.  What Is the Impact of Lockdowns on Dengue?

Authors:  Oliver Brady; Annelies Wilder-Smith
Journal:  Curr Infect Dis Rep       Date:  2021-01-21       Impact factor: 3.663

5.  New genotype invasion of dengue virus serotype 1 drove massive outbreak in Guangzhou, China.

Authors:  Mengmeng Ma; Sean Wu; Zhenjian He; Lihong Yuan; Zhijun Bai; Liyun Jiang; John Marshall; Jiahai Lu; Zhicong Yang; Qinlong Jing
Journal:  Parasit Vectors       Date:  2021-02-27       Impact factor: 3.876

6.  Dengue 2 serotype and yellow fever coinfection.

Authors:  Flávia Gehrke; Katharyna Cardoso Gois; Beatriz da Costa Alves Aguiar Reis; Gabriel Zorello Laporta; Fernando Luiz Affonso Fonseca
Journal:  Access Microbiol       Date:  2021-12-17

Review 7.  Dengue vaccine development by the year 2020: challenges and prospects.

Authors:  Annelies Wilder-Smith
Journal:  Curr Opin Virol       Date:  2020-10-18       Impact factor: 7.090

8.  Assessing the impact of COVID-19 border restrictions on dengue transmission in Yunnan Province, China: an observational epidemiological and phylogenetic analysis.

Authors:  Naizhe Li; Yun Feng; Bram Vrancken; Yuyang Chen; Lu Dong; Qiqi Yang; Moritz U G Kraemer; Oliver G Pybus; Hailin Zhang; Oliver J Brady; Huaiyu Tian
Journal:  Lancet Reg Health West Pac       Date:  2021-08-20

9.  Secondary Analysis of the Efficacy and Safety Trial Data of the Tetravalent Dengue Vaccine in Children and Adolescents in Colombia.

Authors:  Humberto Reynales; Gabriel Carrasquilla; Betzana Zambrano; Margarita Cortés S; Tifany Machabert; Jin Jing; Sophie Pallardy; Owen Haney; Martha Faccini; Juliana Quintero; Fernando Noriega
Journal:  Pediatr Infect Dis J       Date:  2020-04       Impact factor: 3.806

10.  Adapting Rapid Diagnostic Tests to Detect Historical Dengue Virus Infections.

Authors:  Fernando Echegaray; Peter Laing; Samantha Hernandez; Sully Marquez; Amanda Harris; Ian Laing; Adam Chambers; Neil McLennan; Victor A Sugiharto; Hua-Wei Chen; Sandra Vivero Villagran; Abigail Collingwood; Magelda Montoya; Fausto Bustos Carrillo; Mark P Simons; Philip J Cooper; Andrea Lopez; Gabriel Trueba; Joseph Eisenberg; Shuenn-Jue Wu; William Messer; Eva Harris; Josefina Coloma; Leah C Katzelnick
Journal:  Front Immunol       Date:  2021-07-23       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.